Last updated: April 24, 2026
What is EP1890684 and what does it protect?
EP1890684 is a European Patent Office (EPO) patent application/publication that covers a drug-related invention. It is cited in the EPO and European-wide patent workflow as a granted or pending right depending on family member status in national phases. The scope is defined by the claim set attached to the published application and any subsequent claim amendments in grant. Without the underlying claim text and bibliographic status, a complete claim-by-claim construction and enforceable scope cannot be produced.
What is the scope of the claims in EP1890684?
A full scope analysis requires the exact independent claim(s) and dependent claim(s) as published and, if applicable, as granted. Claim scope in drug patents at the EPO typically turns on:
- Product-by-process vs product language
- Active ingredient definition (chemical name, formula, Markush groups, salts, solvates)
- Therapeutic indication limits (use claims, second medical use, or implicit medical use)
- Method-of-treatment steps (dosing regimen, patient selection, administration route)
- Formulation elements (dosage form, excipients, release profile)
- Biomarker and patient stratification (if present)
- Manufacturing parameters (if present)
For EP1890684, a complete mapping of these elements to specific claim language is not possible here because the claim text itself is not provided and cannot be reconstructed reliably from the identifier alone.
What is the patent landscape around EP1890684 across Europe?
A European patent landscape assessment requires at least:
- The family (priority application and related filings: PCT/WO and national equivalents)
- The grant status by key EPC member states (EP, DE, FR, IT, ES, NL, SE, CH, UK if still relevant, etc.)
- The term status (including any Supplementary Protection Certificates where applicable)
- The relevant prior art against novelty and inventive step
- The ongoing litigation/opposition history (EPO oppositions, national challenges)
- Competing patents with overlapping claim boundaries (same drug substance, polymorph/formulation, second medical use, or manufacturing)
A complete European landscape for EP1890684 cannot be generated without the family identifiers and the substantive claim content. Any attempt to list competing EPs or map likely overlaps would be speculative.
How would EPO claim construction likely treat EP1890684?
For a drug patent under the EPO Boards of Appeal framework, claim scope and enforceability usually depend on:
- Article 84 clarity: whether key terms (drug definition, patient group, dose ranges) are precise
- Article 54 novelty: whether the entire combination of features exists in one prior art document
- Article 56 inventive step: whether the distinguishing features would have been obvious to the skilled person
- Article 123(2) compliance: if amendments were made during prosecution or opposition
- Claim interpretation: whether the claim is limited to explicitly defined embodiments or can cover broader equivalents through general language (notably Markush, ranges, “comprising,” and functional limitations)
To perform that analysis, the exact claim wording is required, including the independent claim structure and any abbreviations or defined terms.
Are there likely SPCs (Supplementary Protection Certificates) tied to EP1890684?
SPCs in Europe depend on:
- The existence of an authorized medicinal product covered by an effective patent
- The presence of a patent that protects the product “as a whole” or the active ingredient “in itself” (in practice, the effective claim set and designation matter)
- The timing of applications and regulatory marketing authorization
Whether EP1890684 is designated as the “basic patent” for any SPC in EU member states requires the regulatory link and the published SPC registers. That data cannot be derived from the EP identifier alone without the underlying bibliographic record and the regulatory authorization connection.
What is the actionable outcome for business decisions?
With the claim text and family/regulatory links absent, this task cannot produce a reliable:
- Claim chart (feature-by-feature)
- Freedom-to-operate (FTO) cut for EU jurisdictions
- Validity risk mapping (novelty and inventive-step attack points)
- Design-around options grounded in actual claim boundaries
- SPC exposure analysis by member state
Key Takeaways
- EP1890684’s enforceable scope and claim breadth cannot be accurately constructed without the published/granted claim set and family bibliographic status.
- A complete European patent landscape requires family identifiers, grant and opposition status by jurisdiction, and claim language to identify overlaps with competing inventions.
- SPC linkage and market exclusivity implications cannot be assessed without the regulatory authorization tie to the effective claims.
FAQs
-
What does “EP1890684” include: the drug substance, formulation, or indication?
Without the claim text attached to the specific publication/grant, the covered subject matter cannot be determined.
-
Does EP1890684 have an associated SPC in EU member states?
SPC eligibility depends on the “basic patent” and regulatory authorization linkage, which cannot be established from the identifier alone.
-
Is EP1890684 likely to be attacked for novelty or inventive step?
The attack points depend on the exact distinguishing features in the independent claim and the closest prior art citations.
-
Which European countries would be the highest enforcement priority for EP1890684?
Enforcement priority tracks where EP rights are validated and whether the patent was granted, which depends on the family status.
-
Can generic or biosimilar entrants design around EP1890684?
Design-around strategies must be grounded in the claim boundaries and dependent-claim limitations; those are not available here.
References
[1] European Patent Office. EP1890684 publication/bibliographic record (EPO Register of European Patents).
[2] European Patent Office. EPO patent opposition and proceedings framework (Articles 54, 56, 84, 123(2), EPC).
